Human tumors grown as xenografts in immunodeficient nude mice are widely used to investigate the pharmacological activities of anticancer drugs. Drug-metabolizing enzymes and transporters are expressed in tumor cell lines and changes in drug metabolism and pharmacokinetics (DMPK)-related gene expression after inoculation of the tumor cell may affect the pharmacological activity of the drug under consideration. The aims of the current study were to characterize DMPK-related gene expression profiles and responses to typical cytochrome P450 inducers in monolayer carcinoma cells grown in tissue culture versus those inoculated into a xenograft model. We used the human hepatocellular carcinoma cell line PLC/PRF/5 for this study and comprehensively assessed changes in DMPK-related gene expression by reverse transcriptionpolymerase chain reaction quantitation. CYP3A4 and UDP-glucuronosyltransferase 1A protein amounts were also analyzed by immunoprecipitation followed by immunoblotting. We found that the expression of many DMPK-related genes was elevated in the inoculated tumor compared with the monolayer carcinoma cells, indicating changes in their gene regulation pathways, presumably due to modulation of the nuclear receptor family of transcription factors. In addition, monolayer carcinoma versus inoculated tumor cells showed different responses to rifampicin, but similar responses to dexamethasone or 3-methylcholanthrene. These results suggest that inoculation of tumor cells results in the activation of drug metabolism and transport function, leading to changes in the responses to pregnane X receptor ligands and consequent discrepancies in the pharmacological activities between in vitro monolayer carcinoma cells and in vivo xenograft models.
Drug-metabolizing enzymes and transporters play central roles in the metabolism, elimination, and detoxification of xenobiotics and drugs introduced into the human body. The process of drug disposition can be divided into three phases: phase I, oxidation by enzymes; phase II, conjugation by enzymes; and phase III, elimination by transporters (Nakata et al., 2006) . The phase I system involves cytochrome P450 (P450) and flavin mixed-function oxidase, microsomal monooxygenases that catalyze the oxidation of numerous xenobiotics. Phase II enzymes catalyze the conjugation of certain drugs and a large number of phase I metabolites. Transporters in the phase III system eliminate parent drug and/or phase I/II metabolites from cells. In addition to phase I, II, and III proteins, several nuclear receptors (xenosensors) are critically involved in the induction (up-regulation) or suppression (down-regulation) of various important enzymes and transporters (Xu et al., 2005) . Yu et al. (2001) have described the P450 activities in the National Cancer Institute tumor cell line panel, which consists of 60 cell lines from 9 tumor types. A survey of CYP3A expression in a wide range of human cancers from clinical samples by immunohistochemistry revealed expression of CYP3A with the following frequencies: gastric adenocarcinoma (30%), transitional cell carcinoma (68%), breast carcinomas (30%), sarcomas (78%), and renal clear cell cancers (100%) (Patterson and Murray, 2002) .
Human tumors grown in xenograft models using immunodeficient mice are widely used to investigate the pharmacological activities of antitumor drugs. Drug-metabolizing enzymes and transporters are present in tumors (Michael and Doherty, 2007) including carcinoma cell lines, and are capable of the biotransformation of a variety of antitumor drugs. Therefore, drug-metabolizing enzymes and transporters in tumors can provide both a potential mechanism of resistance and a means of achieving optimal therapy. Cells in solid tumors exist in a diversity of microenvironments and are often subjected to large concentration gradients of drugs that diffuse in from the blood vessels. In contrast, cells in monolayer carcinoma cultures are generally exposed to a uniform environment and concentration of drug. Thus, the in vitro screening of antitumor drugs using monolayer carcinoma cells does replicate the complex pathophysiology of cancers, including the large intervascular distances that are encountered in many tumors (Minchinton and Tannock, 2006) . In fact, experimental results with doxorubicin are consistent in showing limited penetration into spheroids and consequently reduced activity against centrally located cells (Erlichman and Vidgen, 1984; Durand, 1990) . This has been more recently confirmed in studies of multilayered cell cultures and tumors (Kyle et al., 2004) . In the xenograft model, the host is a nonhuman animal species, and the tumor is from a humanderived cell line. We have previously reported the effect of tumor inoculation on drug-metabolizing enzymes and transporters in the host liver (Sugawara et al., 2009 ). However, differences in the expression levels of drug-metabolizing enzymes and transporters between monolayer carcinoma cells and inoculated tumors are not clearly understood. Guengerich and Turvy (1991) showed that the expression of CYP1A2, CYP3A, and CYP2E1 in cirrhotic liver tissues were low compared with those in normal liver tissues, whereas the expression of CYP2C was higher in metastatic liver tissues. These reports indicate that the patterns of drug-metabolizing enzymes and transporters differ between tumor and normal tissues. The drug-metabolizing enzymes in xenograft tumors are reported to be induced by P450-inducing agents (Smith et al., 1993) . However, it is unclear how similar the regulation and induction of DMPK-related genes are in tumors versus their tissue of origin. Therefore, we examined DMPK-related gene expression profiles in both monolayer carcinoma cell lines and in tumors inoculated as xenografts into nude mice. These data may provide useful information for the development of antitumor drugs.
In this study, we examined gene expression in both monolayer carcinoma cultures of the hepatocellular carcinoma cell line, PLC/ PRF/5, and tumors formed by inoculation of this cell line in a subcutaneous xenograft model. The mRNA levels of drug-metabolizing enzymes and transporters were measured by real-time reverse transcription-PCR to compare basal expression and the response to P450 inducers between monolayer carcinoma cells and inoculated tumor cells. We discuss possible mechanisms for differences in DMPK-related gene expression profiles between these two sets of cells.
Materials and Methods
Materials. 3-Methylcholanthrene (MC) was purchased from Aldrich Chemical (Tokyo, Japan). Corn oil was obtained from Wako Pure Chemicals (Osaka, Japan). Dexamethasone (Dex) and rifampicin (Rif) were purchased from Sigma Chemical (Tokyo, Japan).
Cell Culture. The human hepatocellular carcinoma cell line, PLC/PRF/5, was obtained from the Institute of Development, Aging and Cancer at Tohoku University (Miyagi, Japan). The cell line was cultured in Dulbecco's modified Eagle's medium (Sigma-Aldrich, Tokyo, Japan) containing 10% fetal bovine serum (Invitrogen, Tokyo, Japan) in 5% CO 2 and 95% air at 37°C. PLC/PRF/5 cells were detached by gentle trypsinization and seeded at a density of 1 ϫ 10 4 cells/100 l/well in 96-well collagen-coated plates (BD Biocoat, Tokyo, Japan). The inducers MC, Dex, and Rif were dissolved in DMSO and added to monolayer cultures at a final concentration of 0.1% DMSO for 4 consecutive days. For the vehicle control, DMSO was added to 0.1% in final concentration.
Preparation of Xenograft Mice. All animal protocols and studies were approved by the Institutional Animal Care and Use Committee at Eisai Co., Ltd. before the commencement of any experiments. Five-week-old C57BL/ 6-nu/nu female mice were obtained from Clea Japan, Inc. (Tokyo, Japan). Mice were kept in a temperature-controlled facility with 12-h light/dark cycles. Mice were fed a standard chow diet and allowed free access to food and water. Mice were acclimated to these conditions for at least 1 week before tumor inoculation.
Cultured PLC/PRF/5 cells were pelleted after harvesting and resuspended in a 50% Matrigel (BD Biosciences, Tokyo, Japan) in Dulbecco's modified Eagle's medium to a final cell count of 5 ϫ 10 7 cells/ml. Matrigel was used for efficient engrafting of cells in host animals (Cowell et al., 1997; Kulp et al., 2004) . The passage number until injection was 5 times from running stock. A volume of 0.1 ml of the cell suspension was injected subcutaneously in the left flank of each mouse. Mice were weighed, and caliper measurements of the subcutaneous tumor were made three times weekly. The tumor volume (in cubic millimeters) was calculated using the equation (l ϫ w 2 )/2, where l and w refer to the larger and smaller dimensions collected at each measurement.
Compound Treatment. When the tumor volume reached approximately 300 mm 3 , mice were randomized into control and treatment groups and were given intraperitoneal injections of corn oil (10 ml/kg, control), MC (100 mg/kg), Dex (100 mg/kg), or Rif (100 mg/kg) once daily for 4 consecutive days. The inducers, MC, Dex, and Rif, were all suspended in corn oil. The treatment groups consisted of control (vehicle) group (n ϭ 3), MC-treated group (n ϭ 4), Dex-treated group (n ϭ 4), and Rif-treated group (n ϭ 4). Tumors grown in mice were collected at 24 h after the last treatment, frozen in liquid nitrogen, and stored at Ϫ80°C until processed and analyzed.
RNA Extraction. Frozen tumor tissue was homogenized using with a multibead shocker (Yasui Kikai, Osaka, Japan) and divided into aliquots for protein assay and RNA extraction. For RNA extraction, TRIzol reagent (Life Technologies Japan Ltd., Tokyo, Japan) was added to the aliquot, followed by chloroform extraction, and total RNA was purified with an RNeasy Mini Kit (QIAGEN, Tokyo, Japan). For the monolayer carcinoma cell lines, cells were lysed with Lysis Solution (Applied Biosystems, Tokyo, Japan), and total RNA was purified using the ABI PRISM 6100 PrepStation (Applied Biosystems) according to the manufacturer's protocol. The concentration of purified RNA was measured with a NanoDrop spectrophotometer (SCRUM Inc., Tokyo, Japan), and its quality was assessed with a 2100 Bioanalyzer (Agilent Technologies, Tokyo, Japan).
Reverse Transcription Reaction. cDNA was synthesized from 2 g of total RNA using a High-Capacity cDNA Transcription Kit (Applied Biosystems). In brief, 2 l of 10ϫ Reverse Transcription Buffer, 0.8 l of 25ϫ dNTPs, 2 l of random primers, 1 l of MultiScribe reverse transcriptase (50 U/l), and 0.8 l of nuclease-free water were combined in a 96-well plate. Reverse transcription was performed on a GeneAmp PCR 9700 system (Applied Biosystems) for 10 min at 25°C, followed by 120 min at 37°C, and terminated at 95°C for 10 min.
Quantitative Real-Time PCR. TaqMan and SYBR Green protocols were used to amplify cDNAs of each mRNA of interest by real-time quantitative PCR using a 7900HT PCR system (Applied Biosystems). The primers and TaqMan probes designed for this study were synthesized by Sigma Genosys (Hokkaido, Japan) and are listed in Supplemental Data 1 (Nishimura et al., 2002; Nishimura and Naito, 2005) . Primer and probe sets for CYP2E1, CYP3A7, CYP4A11/22, and SLCO2B1 were obtained from Applied Biosystems. Primer sets for ABCB1, ABCC2, ABCC4, ABCC6, ABCG2, SLC10A1, SLCO1B1, SLCO1B3, SLCO2B1, AhR, ARNT, FOXO1, HNF1A, HNF4A, NRF2L2, NR0B2, NR1H2, NR1H3, NR1H4, NR1I1, NR1I3, NR3C1, NR5A2, PPARA, and PPARGC1A were obtained from Takara Bio (Shiga, Japan).
PCR amplifications were carried out in 12-l reaction volumes consisting of 5 l of cDNA template, 6 l of PCR Master Mix, 200 nM forward primer, and 200 nM reverse primer in a 384-well plate. In the TaqMan assays, 200 nM TaqMan probe was also added to the above reaction mixture. Reactions were heated at 95°C for 10 min, followed by 50 cycles of amplification consisting of denaturation at 94°C for 15 s, and annealing and extension at 60°C for 1 min. The mRNA levels of the dilution series (from 0.0167 to 167 ng/l) of a standard RNA sample were obtained from human liver total RNA (Takara Bio), and the level of each mRNA of interest was normalized to that of glyceraldehyde-3-phosphate dehydrogenase mRNA. Results were then ex-
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To obtain a global view of treatment-related changes in gene expression, cluster analysis was performed on signal log ratios with the cluster package of R (version 2.8.1) using the Pearson correlation distance.
Microarray Protocol. From each xenograft and monolayer carcinoma cell culture 700 ng of total RNA was reverse-transcribed into doublestranded cDNAs using Molony murine leukemia virus reverse transcriptase and amplified for 2 h at 40°C using the Quick Amp Labeling Kit (Agilent Technologies). Subsequently, cDNAs were transcribed into antisense cRNA and labeled with Cy3-CTP fluorescent dyes for 2 h at 40°C according to the manufacturer's protocol. Cy3-labeled cRNAs were purified using the RNeasy Mini Kit (QIAGEN). Purity and dye incorporation were assessed using a NanoDrop spectrometer and the Bioanalyzer. Minimal acceptable Cy3 labeling was Ͼ1.0 pmol/l. Next, 1.65 g of Cy3-RNAs was hybridized to 4 ϫ 44K Whole Human Genome Oligo Microarrays using a Hybridization Kit (Agilent Technologies).
After a 17-h incubation at 60°C and 10 rpm rotation, microarrays were washed with two buffers (Agilent Technologies): buffer 1 containing 0.005% Triton X-102 for 1 min and then buffer 2 at 37°C for 1 min. Microarrays were scanned with the Microarray G2505B scanner (Agilent Technologies) with the extended dynamic range scan mode to scan the same slide at two different levels, and data were extracted and normalized from the resulting images using Feature Extraction software (version 9.5.3.1; Agilent Technologies).
Quality Evaluation and Comparability of Gene Expression Profiles. Fluorescence intensities of scanned images were quantified, corrected for background, and normalized to 75 percentile per chip. Normalization algorithms and background subtractions using Feature Extraction were automatically applied to each array to reduce systematic errors and to adjust for effects due to technological rather than biological variations. Poor-quality features were flagged. Detection call was used to determine whether a transcript was measurable (present), undetectable (absent), or uncertain (marginal) (for a more detailed explanation of the algorithm, see Agilent Technical Note, Publication Number 5988 -6932EN). Probe sets whose detection calls were present or marginal in all samples were used for the following analysis. -Fold change was calculated as normalized ratios of log signal.
Pathway Analyses of mRNA Data Sets. Biological functions and pathways associated with the patterns of gene expression were generated and analyzed using Ingenuity Pathway Analysis (IPA) software (version 6.3; Ingenuity Systems, www.ingenuity.com). Genes from the data set whose normalized intensity was Ͼ10 and p value was Ͻ0.05 using Welch's t test were considered for further analysis by IPA Knowledge Base. Fisher's exact test was used to calculate a p value determining the probability that each biological function and/or disease assigned to that data set is due to chance alone.
Immunoprecipitation. Frozen tumors or cells were homogenized with Complete Lysis M buffer (Roche Diagnostics KK, Tokyo, Japan) containing 1% Nonidet P-40 (Thermo Fisher Scientific KK, Kanagawa, Japan) using a pestle homogenizer (As One, Osaka, Japan) and centrifuged at 8000g for 1 min. The concentration of protein in the supernatant fraction was measured by the BCA protein assay (Bio-Rad Laboratories, Tokyo, Japan). Tumor or cell lysate was used for immunoprecipitation of CYP3A4 and UGT1A. In brief, 1 l of CYP3A4 primary antibody mouse monoclonal IgG (Japan BD, Tokyo, Japan) or UGT primary antibody sheep polyclonal IgG (Cypex, Dundee, UK) was added to 500 g of lysate from each sample and incubated for 1 h at 4°C on a rotary shaker. Then 50 l of resuspended protein G-Sepharose (GE Healthcare Bio-Sciences KK, Tokyo, Japan) was added and incubated for 1 h at 4°C on a rotary shaker. Next, the sample was centrifuged at 5000g for 2 min at 4°C, and the supernatant was carefully aspirated and discarded. The pellet was washed five times with Complete Lysis M buffer containing 1% Nonidet-40, each time repeating the centrifugation step mentioned above. After the final wash, aspiration, and discarding of supernatant, the pellet was resuspended in 30 l of 3ϫ electrophoresis sample buffer (Bio-Rad Laboratories) and 5 to 10 l of supernatant was used for Western immunoblotting.
Western Immunoblotting. Protein lysates (80 g/lane) were loaded onto 10% SDS-polyacrylamide gels (Cosmo Bio Ci., Ltd., Tokyo, Japan), subjected to electrophoresis, and transferred to Immun-Blot polyvinylidene difluoride (PVDF) membranes (0.2 m; Bio-Rad Laboratories). The PVDF membrane was incubated in PVDF blocking buffer (Toyobo Co., Ltd., Osaka, Japan) for CYP3A4 or Starting Block (Bio-Rad Laboratories) for UGT1A for 1 h. Primary antibodies [anti-human CYP3A4 (Nosan Corporation, Kanagawa, Japan) and anti-human UGT1A (Japan BD)] were diluted 1:3000 with blocking buffer for CYP3A4 and 1:500 with Can Get Signal Immunoreaction Enhancer Solution 1 (Toyobo Co., Ltd.) for UGT1A. PVDF membranes were incubated in primary antibody overnight at 4°C, after which they were washed three times for 5 min in Tris-buffered saline containing 0.5% Tween 20. Membranes were then incubated with the appropriate secondary antibody for 1 h, either goat anti-rabbit IgG-horseradish peroxidase (1:10,000 for detection of CYP3A4 or 1:10,000 for UGT; Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Subsequently, membranes were washed three times for 5 min, and immunostaining was detected by chemiluminescence using the SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific KK) for CYP3A4 or the ECL Plus Western Blotting Detection System (GE Healthcare BioSciences KK) for UGT. Image capture was performed with an LAS-3000 system (FUJIFILM Corporation, Tokyo, Japan), and image analysis was carried out with MultiGauge software (FUJIFILM Corporation).
Statistical Analysis. Data are expressed as mean Ϯ S.E.M. Statistical analyses were performed with Prism 5.01 (GraphPad Software, Inc., San Diego, CA). Analysis of variance followed by Tukey's post hoc test was used to compare the data from three or more treatment groups. Student's t test was used in the case of two groups. P Ͻ 0.05 compared with control was regarded as statistically significant, which is shown in each figure with an asterisk.
Results
Differentiation Marker Analyses. Albumin (ALB), a liverselective protein, and ␣-fetoprotein (AFP), the fetal homolog of albumin, can be used as markers of the differentiation status of liver in vitro. Because the synthesis of AFP is turned off shortly after birth, its detection indicates the loss of the differentiated liver phenotype and reversion to a more fetal status. Analyses of their mRNA levels revealed that ALB and AFP were increased 55-and 536-fold in inoculated tumor compared with monolayer carcinoma cells, respectively (Fig. 1) . Table 1 . Expression levels of nearly all of the DMPK-related genes were higher in inoculated tumor than in monolayer carcinoma cells. Expression levels of CYP1A2 and ABCB11 were under the detection limit (C t Ͼ40 cycle) in all samples.
The mRNA expression of all UGTs studied was higher in the inoculated tumor. Among the UGTs, UGT2B11, UGT2B10, and UGT2B7, were significantly higher (118-, 55-, and 47-fold, respectively). For P450s, CYP2C18, CYP2C8, CYP2C9, CYP3A4, CYP3A5 , and CYP3A7 mRNA levels were significantly elevated in inoculated tumor. In particular, CYP3A4, CYP3A5, and CYP3A7 expressions were dramatically increased (ϳ55-fold). Among transporter genes, ABCC2, ABCC6, ABCG2, SLC22A2, SLCO1B1, SLCO1B3, and SLCO2B1 mRNA levels were significantly higher in inoculated tumor cells, especially SLCO1B3 (42-fold), SLC22A2 (17-fold), and SLCO1B1 (10-fold). The increases in ABCB4, SLC10A1, and SLC22A1 mRNAs were not statistically significant. The decreases in CYP2B6 and ABCB1 mRNAs were not statistically significant. In the case of the NR examined, FXR, PXR, and CAR, which are important transcriptional regulators of drug-metabolizing enzymes and transporters, showed significant increases (more than 10-fold), whereas other NRs were the same or lower in the inoculated tumor.
Immunoprecipitation, Western Immunoblotting, and Comparison of CYP3A4 and UGT1A Protein Expression between Monolayer Carcinoma Cells and Inoculated Tumor. Because we observed elevated levels of P450s and UGTs mRNAs in inoculated tumors, we analyzed CYP3A4 and UGT1A protein levels by immunoprecipitation followed by Western immunoblotting. We observed a significant 3.2-fold increase in immunoreactive protein levels for CYP3A4 and an 8.8-fold increase for UGT1A (Fig. 2) .
Pathway Analysis of Genes Affected by Tumor Inoculation. We used IPA software to assess the functional pathways affected by the significant changes in gene expression that resulted from tumor inoculation. Probe sets representing the differentially expressed genes between monolayer carcinoma cells and inoculated tumors were selected by following criteria and as described under Materials and Methods. The gene identification was mapped to corresponding data in the IPA Knowledge Base to analyze gene pathways, but gene identification was unmapped because it does not exist in the IPA Knowledge Base or not match known gene products, e.g., expressed sequence tags. The mapped probe sets (4929 probe sets) were used for analysis (6223 probe sets were statistically significant in total and unmapped probe sets were not used for analysis). pathways overlapped considerably, especially in xenobiotic metabolism; however, the analysis suggests that many of the modulated genes were directly related not only to xenobiotic metabolism and its accompanying gene regulation but also to inflammation.
Comparison of the Response to P450 Inducers between Carcinoma Cells and Inoculated
Tumor. Clustering of sample data was performed using 36 DMPK-related genes after removal of 9 genes. P450s, UGTs, transporters, and five nuclear receptors (AhR, Arnt, NR1I2, NR1I3, and PPARA) were selected for analysis. CYP1A2 and ABCB11 were excluded from analysis because their mRNA levels were undetectable in all samples. CYP2A6, CYP4A11/22, ABCB1, ABCB4, SLC10A1, SLC22A1, and SLC22A2 were excluded because their expressions in control samples in either monolayer carcinoma cells or inoculated tumors were under the detection limit. These responsive DMPK-related genes were clustered in two dimensions with respect to each inducer (Fig. 5, A and B) . The resulting heat map indicates that MC and Dex treatment have similar effects on monolayer carcinoma cells and inoculated tumor, whereas the effects of Rif were clearly distinct between inoculated tumor and monolayer carcinoma cells.
Discussion
We comprehensively assessed differences in DMPK-related gene mRNA expression between monolayer carcinoma cells of the hepatocellular carcinoma cell line PLC/PRF/5 and tumors resulting from inoculation of this cell line into mice as xenografts.
Differentiation Markers. The degree of hepatic maturation is characterized by the expression of liver-and stage-specific genes (Panduro et al., 1987) . For example, ALB, the most abundant protein synthesized by hepatocytes, is initially expressed at lower levels in early fetal hepatocytes, and then increases as the hepatocytes mature, reaching a maximum in adult hepatocytes (Tilghman and Belayew, 1982) . The increased expression of ALB in inoculated tumor suggests that liver function would be activated after inoculation of these cells. In contrast, AFP is an early hepatic marker expressed by hepatoblasts in the liver bud until birth, after which its expression is dramatically reduced (Spear, 1999) . Furthermore, isoforms of CYP3A also exhibit different expression levels in liver during developmental stages; CYP3A7 is mainly expressed in human fetal liver, whereas CYP3A4 is the predominant isoform in adult hepatocytes (Matsunaga and Shiro, 2004) . After inoculation of tumor, the expression of AFP and CYP3A7 ( Fig. 1; Table 1 ) dramatically increased, which may be the result of reactivation of fetal promoters, perhaps resulting from a dedifferentiation process or change in methylation status (Dannenberg and Edenberg, 2006) during the development of the tumor. These results suggest that native characters in the cell may be altered after the formation of tumors in animals.
Basal Gene Expression. The expression of most mRNAs encoding drug-metabolizing enzymes and transporters were increased after inoculation of tumor cells into animals (Table 1 ). CYP3A4 and UGT1A protein levels, as determined by immunoreactivity, were significantly higher in inoculated tumor versus monolayer carcinoma cells (Fig. 2) . These results indicate that drug metabolism and transport functions would be enhanced after inoculation of monolayer carcinoma cells even if the expression level of CYP3A4 did not reach that of human hepatocytes. CYP3A4 comprises up to 30% of total hepatic P450 protein with ϳ55% of all drugs being metabolized by this enzyme (Shimada et al., 1994; Zuber et al., 2002) . Thus, CYP3A4 is involved in the metabolic clearance of most commonly used antitumor drugs, including newer molecular targeted agents such as gefinitib and imatinib (Kacevska et al., 2008) . In addition, antitumor drugs are metabolized not only by P450s but also by transferases (Harmsen et al., 2007) . For example, SN-38, the active metabolite of irinotecan (CPT-11), undergoes significant glucuronidation to form inactive glucuronide. A strong correlation was observed between UGT1A1 alleles having different promoter activities and the corresponding rate of glucuronidation of SN-38 (Iyer et al., 1999) . Thus, the increased expression of P450s and UGTs in inoculated tumor could result in the altered pharmacological activity of antitumor drugs compared with monolayer carcinoma cells.
We observed that two members of the solute carrier organic anion transporter (SLCO) family, SLCO1B3 and SLCO1B1, were significantly up-regulated in inoculated tumors. This family of transporters has been shown to be expressed in certain cancers (Okabe et al., 2008) . Based on the ability of these transporters to transport methotrexate and paclitaxel, and their known broad multispecificity (Hagenbuch and Gui, 2008) , we would expect that the uptake of antitumor drugs would be enhanced in inoculated tumor compared with monolayer carcinoma cells. For example, Nozawa et al. (2005) showed that SN-38 is a substrate of SLCO1B1 using HEK293 cells stably expressing SLCO1B1. Similar to organic anion transporters, organic cation transporters also play an important role in the transport of drugs. The present study clearly demonstrated that the mRNA levels of SLCO1B3 and organic cation transporters were elevated in inoculated tumor. Thus, antitumor drugs may be taken up into inoculated tumor more efficiently than into monolayer carcinoma cells, resulting in the greater inactivation of the parent drugs or greater formation of their metabolites. This alteration in transporter expression could also affect the pharmacological activity or toxicity of compounds due to the inoculated tumor. These results suggest that assessment of in vitro pharmacological activity using monolayer carcinoma cells may not completely represent the activities in xenograft models, because of elevated metabolism and transport activities in the xenografts.
Based on microarray results, the top Canonical Pathways exhibiting altered basal gene expression were LPS/IL-1 Mediated Inhibition of RXR Function and Acute Phase Response. The former is involved in the regulation for many drug-metabolizing enzymes and transporters via CAR/RXR, PXR/RXR, PPAR/RXR, FXR/RXR, LXR/RXR, and the latter is important for the regulation of ALB, APOA, and HMOX via TCF, NFkB, GCR, IkB and TNFR. These pathways indicate that inflammation may occur at least locally in xenograft tumors inoculated into immunodeficient mice and further suggest that inflammation may be one stimulus responsible for the increase in basal expression of drug-metabolizing enzymes. This result is in contrast to studies suggesting that inflammation causes a decrease in the expression of drug-metabolizing enzymes and increased drug clearance (Aitken et al., 2006; Robertson et al., 2008) . According to the Ingenuity Pathway Analysis, factors that are common in the upstream of these two pathways include MYD66, TRAF6, ILR, and TNFR, which may be related to activation of nuclear receptors, such as CAR and PXR (Supplemental Data 2 and 3).
On the other hand, the method of cell culture has been reported to affect gene expression and cell function. Zietarska et al. (2007) reported that spheroid/xenograft models and monolayer carcinoma cultures of the ovarian cancer cell line, OV-90, differ in various aspects of their cytoskeletal remodeling such as cell shape, cell movement, intracellular transport, contractile ring formation, and chromosome movement. These results are similar to the alterations in Physiological System Development seen in our study. Regulation of cellular processes linked to oncogenic transformation such as proliferation, contact inhibition, cell growth, and apoptosis are also affected by changes in cytoskeleton (Pawlak and Helfman, 2001 ). These results suggest that the expression of genes for drug-metabolizing enzymes could be affected by the microenvironment in xenograft tumor and/or by tumor-host interaction.
Comparisons of monolayer versus spheroid cultures of human liver hepatocellular carcinomas showed that liver-specific P450 activity and albumin production are higher in the spheroids (Chang and Hughes-Fulford, 2009 ). Thus, a better correlation to in vivo DMPK might be obtained by using an in vitro screening system with spheroid cultures.
The regulation of P450 and UGT gene expression by a variety of nuclear receptors results in variability among individuals in basal protein levels and activities in human liver (Wortham et al., 2007) . For example, the inhibition of PXR mRNA expression by human PXRsmall interfering RNA caused changes in the basal and ligandactivated mRNA levels of CYP2A6, CYP2C8, CYP3A4, and CYP3A5 (Kojima et al., 2007) . UGT1A1 has also been reported to be regulated by CAR, PXR, and AhR (Zhou et al., 2005) . Treatment of HepG2 cells with the synthetic FXR agonist GW4064 resulted in higher UGT2B4 expression and glucuronidation activity, suggesting that UGT2B4 is a direct transcriptional target of FXR (Barbier et al., 2003) . These reports indicate that the basal expression of DMPKrelated genes is related to the expression levels of nuclear receptors such as CAR, PXR, and FXR. Thus, the increase in basal gene expression of P450s and UGTs that we observed in inoculated tumor may be caused by the transcriptional up-regulation of these nuclear receptors, as shown in our study. Induction Response. Understanding the effect of drugs on the induction of enzyme expression or activity is important in drug discovery and development, because this can underlie the drug-drug interactions that affect pharmacokinetics/pharmacodynamics. Thus, understanding drug-metabolizing enzyme induction in tumor would be useful for oncology drug development. Our heat map results show that MC and Dex treatments have similar effects in monolayer carcinoma cells and inoculated tumor. In contrast, the effects of Rif were distinct from those of MC and Dex. MC is a ligand for AhR, which heterodimerizes with the AhR nuclear translocator Arnt. Dex is a ligand for rodent but not human PXR, whereas Rif is a PXR ligand in humans but not in rodents (Moore et al., 2000) . On the other hand, it might be related to basal expression of CYP3A4 in tumor. That is, the basal expression of CYP3A4 was significantly increased in tumor, but its induction was less in tumor. It is likely that the minimal induction response was observed in higher basal expression in human hepatocytes, for example, CYP2B6, CYP2C9, and CYP3A4 after treatment with phenobarbital in human hepatocytes (Olsavsky et al., 2007) and testosterone 6␤-hydroxylase activity by paclitaxel and rifampicin in human hepatocytes (Kostrubsky et al., 1999) . Among nuclear receptors, AhR (and Arnt) activity was shown to be similar between monolayer carcinoma cells and inoculated tumor, whereas PXR activity increased after tumor inoculation. Thus, the distinct effects of Rif treatment between monolayer carcinoma cells and inoculated tumor may be due to differences in basal PXR expression.
In conclusion, we observed that the expression of drug-metabolizing enzymes and transporters increased after inoculation of tumor cells into animals. Our data indicate that this is due primarily to the up-regulation of the DMPK-related gene regulation pathway resulting from up-regulated nuclear receptor expression. The capacities of drug metabolism and transport are thus augmented after inoculation of tumor, which may cause discrepancies between the in vitro and in vivo activities of antitumor drugs. In addition, differences due to Rif treatment were also observed between the in vitro and in vivo systems, which could also lead to discrepancies when the antitumor drug is a Rif-type inducer. Thus, the antitumor activities of compounds in xenograft animals may deviate from those predicted based on the in vitro potency in monolayer carcinoma cells because the drug levels in inoculated tumor would be influenced by the elevated capacities of drug-metabolizing enzymes and transporters in inoculated tumor, as well as by altered host pharmacokinetics.
